Description: DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Home Page: www.diamedica.com
DMAC Technical Analysis
Two Carlson Parkway
Minneapolis,
MN
55447
United States
Phone:
763 612 6755
Officers
| Name | Title |
|---|---|
| Mr. Dietrich John Pauls MBA | Pres, CEO & Director |
| Mr. Scott B. Kellen C.A. | CFO & Company Sec. |
| Dr. Edward G. Calamai Ph.D. | Consulting Head of Manufacturing |
| Dr. Kirsten L. Gruis M.D., M.S. | Chief Medical Officer |
| Mr. Dominic R. Cundari | Chief Commercial Officer |
| Ms. Julie VanOrsdel Daves CCRP | Sr. VP of Clinical Devel. Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.078 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2008-01-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |